Wegovy Approved for NHS: New Tool to Prevent Heart Attacks and Strokes
The GLP-1 drug semaglutide, known by its brand name Wegovy, is scheduled for availability on the NHS in England from this summer. This treatment aims to prevent heart attacks and strokes in individuals diagnosed with cardiovascular disease, with an estimated 1.2 million people expected to be eligible over the coming years. The introduction follows approval by the National Institute for Health and Care Excellence (NICE) and a cost-effective agreement between the NHS and the drug's manufacturer.
Eligibility and Administration
Draft NICE guidance recommends semaglutide as a treatment option for individuals who have previously experienced a heart attack, stroke, or peripheral arterial disease (a serious circulation problem in the legs). Eligibility is further restricted to those who are also classified as overweight or obese, with a Body Mass Index (BMI) of 27 or higher.
The medication is administered as a weekly injection and is prescribed in conjunction with guidance for a healthy diet and increased physical activity. It can also be used alongside other commonly prescribed medications, such as statins or anti-hypertensives, with the aim of enhancing health outcomes for patients with cardiovascular disease.
Clinical Efficacy and Existing Uses
Clinical trial data indicated that semaglutide reduced the risk of serious cardiovascular events, including heart attacks and strokes, by 20% in overweight individuals with heart and circulatory disease, when compared to a placebo group.
Semaglutide is currently available on the NHS in England for obesity treatment through specialist weight management services. Additionally, Ozempic, another brand name for semaglutide, is prescribed by the NHS for individuals with type 2 diabetes.
Public Health Context
Cardiovascular disease is considered preventable in approximately 70% of cases. The introduction of semaglutide for cardiovascular disease prevention is part of the NHS's 10-Year Health Plan, which focuses on managing long-term conditions, preventing severe complications, and reducing the likelihood of hospital admissions and preventable deaths.
Statements from Health Officials and Advocacy Groups
Helen Williams, National Clinical Director for Cardiovascular Disease Prevention, NHS England
"This treatment could offer a new method to protect hearts and improve health for individuals at high risk of heart attack and stroke. It has the potential to prevent numerous future major cardiovascular events when used with a healthy diet and regular exercise."
Jack Turner, Deputy Director for Medicines Negotiation, NHS England
"Cardiovascular disease is a leading cause of preventable death, and this NHS agreement for an innovative medicine supports the 10-Year Health Plan's objective to prevent and manage long-term conditions."
Health Minister Sharon Hodgson
"Weight loss drugs are proving effective in addressing obesity, and expanding their use for people with cardiovascular disease has the potential to save lives. The government is committed to ensuring these drugs are available to those who need them."
Juliet Bouverie OBE, CEO, Stroke Association
"It's vital that stroke survivors have options to help prevent further strokes. Weight loss medication could be suitable for some when medically recommended, particularly for individuals with disabilities affecting movement. It's important to consider individual needs and alternative medications."
Dr. Sonya Babu-Narayan, Clinical Director, British Heart Foundation
"Semaglutide offers benefits beyond weight reduction and is considered an important medicine for preventing heart attacks and strokes. It's crucial that effective new medicines like semaglutide reach all who could benefit promptly, as cardiovascular disease remains a leading cause of death."